Publish in OALib Journal

ISSN: 2333-9721

APC: Only $99


Any time

2019 ( 5 )

2018 ( 28 )

2017 ( 37 )

2016 ( 36 )

Custom range...

Search Results: 1 - 10 of 1656 matches for " promyelocytic leukemia "
All listed articles are free for downloading (OA Articles)
Page 1 /1656
Display every page Item
Charicleia Kelaidi,Lionel Ades,Pierre Fenaux
Mediterranean Journal of Hematology and Infectious Diseases , 2011, DOI: 10.4084/mjhid.2011.
Abstract: Acute promyelocytic leukemia (APL) with WBC above 10 G/L has long been considered, even in the all-trans retinoic acid (ATRA) era, to carry a relatively poor prognosis (compared to APL with WBC below 10 G/L), due to increased early mortality and relapse. However, early deaths can to a large extent be avoided if specific measures are rapidly instigated, including prompt referral to a specialized center, immediate onset of ATRA and chemotherapy, treatment of coagulopathy with adequate platelet transfusional support, and prevention and management of differentiation syndrome. Strategies to reduce relapse rate include chemotherapy reinforcement with cytarabine and/or arsenic trioxide during consolidation, prolonged maintenance treatment, especially with ATRA and low dose chemotherapy, and possibly, although this is debated, intrathecal prophylaxis to prevent central nervous system relapse. By applying those measures, outcomes of patients with high risk APL have considerably improved, and have become in many studies almost similar to those of standard risk APL patients.
Oral manifestations of acute promyelocytic leukemia: A case report  [PDF]
Daisuke Saito Daisuke Saito, Tadaharu Kobayashi, Yohei Oda, Kanae Niimi, Hiroyuki Kano, Chikara Saito
Open Journal of Stomatology (OJST) , 2013, DOI: 10.4236/ojst.2013.31005

Acute leukemia is often associated with oral manifestations. We report an acute promyelocytic leukemia (APL) case with oral manifestations leading to the diagnosis. A 21-year-old female visited our hospital with complaints of gingival bleeding and swelling of the left lower wisdom tooth. The patient’s complete blood count revealed a marked increase in white blood cells and a decrease in red blood cells and an abnormal leukocyte differential, and APL was diagnosed on the basis of bone marrow samples in the internal medicine department. The patient was treated with all-trans-retinoic acid combined with chemotherapy and has maintained clinical and molecular complete remission at 12 months of follow-up. Dental professionals should be aware of clinical manifestations and complications associated with these malign-

Leucemia promielocítica aguda. Comportamiento clínico
Larquin Comet,José Ignacio; Leyva Diviú,Angelina; León Ramentol,Cira; García Fontes,Yisel;
Revista Archivo M??dico de Camag??ey , 2008,
Abstract: background: acute promyelocytic leukemia is a peculiar form of non- lymphoblastic acute leukemia, with very specific clinical and biological characteristics, that are different from the rest of acute leukemias. objective: to corroborate the clinical characteristics of acute promyelocytic leukemia taking into account its morphologic varieties, as well as clinical and hematologic manifestations. method: a descriptive cross-sectional study in the hematology's department at "manuel ascunce domenech" teaching university hospital of camagüey city was carried out from january 2002 to january 2007. fourteen patients diagnosed of promyelocytic leukemia were studied and the diagnosis in agreement with franco american british classification criteria (fab) was performed, through the realization of the peripheral lamina and the medullary puncture. results: main clinical findings were hemorrhage in skin and mucous and fever. of the total of patients, four sick persons presented complications. of the universe studied, 11 evolved satisfactorily, three had therapeutic failure and two of them die. conclusions: all patients showed thrombocytopenia and the half leukocytosis.
Diagnóstico molecular de la leucemia aguda promielocítica: Resultados preliminares
Martínez Antu?a,Gisela; Cayado Gutiérrez,Niubys; Mu?iz Fernández,Adriana; Espinosa Martínez,Edgardo; Dorticós Balea,Elvira; González Otero,Alejandro; Carnot Uría,José; Fernández Ramos,Oscar; Hernández Ramírez,Porfirio;
Revista Cubana de Hematolog?-a, Inmunolog?-a y Hemoterapia , 2000,
Abstract: acute promyelocytic leukemia (apl) is characterized by the reciprocal translocation t(15; 17) that results in fusion gene pml-rara formation. as apl is considered to be an hematological emergency and also is given a very specific treatment with retinoic acid (atra), then it is very important to diagnose quickly and accurately which makes it possible in many cases to save the patient's life. at present rt- pcr methods have been developed to detect pml-rara gen. these molecular techniques have been extremely useful in diagnosing this entity. this paper sets forth the preliminary results of molecular diagnoses of apl in 38 patients. 36 cases presented the fusion gene and 2 did not. of the total number of positive patients, 19(55%) were bcr 1, 2 (5%) were bcr 2 and 14(40%) bcr 3. all the patients with positive results were responsive to treatment with atra. one of the two patients with negative results showed the existence of t (11; 17). these two patients did not respond to treatment with atra
Melanie Joannides,Ashley N Mays,Anita R Mistry,Syed Khizer Hasan
Mediterranean Journal of Hematology and Infectious Diseases , 2011, DOI: 10.4084/mjhid.2011.
Abstract: Balanced chromosomal translocations that generate chimeric oncoproteins are considered to be initiating lesions in the pathogenesis of acute myeloid leukemia. The most frequent is the t(15;17)(q22;q21), which fuses the PML and RARA genes, giving rise to acute promyelocytic leukemia (APL). An increasing proportion of APL cases are therapy-related (t-APL), which develop following exposure to radiotherapy and/or chemotherapeutic agents that target DNA topoisomerase II (topoII), particularly mitoxantrone and epirubicin. To gain insights into molecular mechanisms underlying the formation of the t(15;17) we mapped the translocation breakpoints in a series of t-APLs, which revealed significant clustering according the nature of the drug exposure. Remarkably, in approximately half of t-APL cases arising following mitoxantrone treatment for breast carcinoma or multiple sclerosis, the chromosome 15 breakpoint fell within an 8-bp “hotspot” region in PML intron 6, which was confirmed to be a preferential site of topoII-mediated DNA cleavage induced by mitoxantrone. Chromosome 15 breakpoints falling outside the “hotspot”, and the corresponding RARA breakpoints were also shown to be functional topoII cleavage sites. The observation that particular regions of the PML and RARA loci are susceptible to topoII-mediated DNA damage induced by epirubicin and mitoxantrone may underlie the propensity of these agents to cause APL.
Ola Khorshid,Amira Diaa,Mohamed Abd El Moaty,Rafat Abd El Fatah
Mediterranean Journal of Hematology and Infectious Diseases , 2011, DOI: 10.4084/mjhid.2011.
Abstract: The current study reports the clinical features and treatment outcome of 67 patients with acute promyelocytic leukemia (APL) presented to National Cancer Institute (NCI-Cairo), in Egypt from January 2007 to January 2011. The median follow-up time was 36 months. All patients were treated with the simultaneous administration of all-trans retinoic acid (ATRA) and anthracyclin. The treatment protocol was modified due to resource limitations at the NCI-Cairo by replacing of idarubicin with doxorubicin in most of the cases and the inclusion of cytarbine during the consolidation phase only in pediatric patients. All patients who achieved molecular complete remission (CRm) after consolidation received two-year maintenance treatment with low dose chemotherapy composed of 6 mercaptopurine, methotrexate and intermittent ATRA courses. The median age at presentation was 29 years. There was a slight male predominance (53%). Bleeding was the most common presenting symptom (79%). Most patients had an intermediate risk Sanz score (49%) and 34% had a high risk score. All patients achieved molecular CR at end of consolidation therapy with a median duration of 100 days. The main therapeutic complications during the induction phase were febrile neutropenia (42%), bleeding (18%) and differentiation syndrome (11%). Five patients died at diagnosis due to bleeding, three died during induction chemotherapy due to febrile neutropenia (n=2) and bleeding (n=1) and one patient died during consolidation therapy due to febrile neutropenia. The 3-year OS was 89% and relapse rate was 3%. Adapting standard AIDA treatment protocols to limited resources by reducing dose-intensity during treatment consolidation, using ATRA in the consolidation phase and alternative anthracyclin (doxorubicin) may be a valid treatment option in developing countries. In spite of the increased incidence of high and intermediate risk score APL in our sample, we reported an acceptable CR rate, toxicity and OS.
Do paradigma molecular ao impacto no prognóstico: uma vis?o da leucemia promielocítica aguda
Jácomo, Rafael Henriques;Figueiredo-Pontes, Lorena Lobo de;Rego, Eduardo Magalh?es;
Revista da Associa??o Médica Brasileira , 2008, DOI: 10.1590/S0104-42302008000100026
Abstract: acute promyelocytic leukemia (apl) is a model of clinical applicability of the knowledge of molecular physiopathology. it is characterized by recurrent genetic involvement of the retinoic acid alpha receptor. the consequence is a protein with low sensibility to its ligand and a myeloid maturation arrest. however, higher doses of all-trans-retinoic acid (atra) are able to supersede this deficiency and this is the mainstay of apl treatment leading to over 80% disease free survival, when adequately treated. epidemiologically, it differs from other acute myeloid leukemia due to a higher incidence in young adults and in countries of "latin" colonization. differing from excellent results observed in developed countries, apl mortality in brazil is still high, despite the wide availability of drugs.
Gemtuzumab ozogamicin in the treatment of adult acute myeloid leukemia  [PDF]
Hiroko Tsunemine, Takayuki Takahashi
Health (Health) , 2013, DOI: 10.4236/health.2013.55A002

Gemtuzumab ozogamicin (GO) is a humanized anti-CD33 monoclonal antibody conjugated to a derivative of an antitumor antibiotic, calicheamicin. GO was approved for the treatment of relapsed acute myeloid leukemia (AML) in the United States (US) in 2000. However, GO was withdrawn from the US market in June 2010, because a large-scale clinical trial failed to show additive or synergistic effects with conventional chemotherapy for newly diagnosed AML. GO is currently available only in Japan. However, several large clinical studies have demonstrated beneficial effects of GO when added to chemotherapy for AML in recent years; therefore, reconsideration of GO availability is gaining attention. Therefore, the role and efficacy of GO as monotherapy or in combination therapy for de novo or relapsed AML should be positively investigated.

Induction of Apoptosis in Human Promyelocytic Leukemia HL60 Cells by Panaxynol and Panaxydol
Zhonghong Yan,Ruolin Yang,Yi Jiang,Zhihui Yang,Junrui Yang,Qian Zhao,Yang Lu
Molecules , 2011, DOI: 10.3390/molecules16075561
Abstract: Panaxynol and panaxydol are naturally occurring polyacetylenes, isolated from the lipophilic fractions of Panax notoginseng, that exert anti-proliferative effects against malignant cells. However, to the best of our knowledge, no study concerning the inhibitory effects of the two polyacetylenes on cell growth of human promyelocytic leukemia cells has been reported. In this paper, we examined the antiproliferation and proapoptotic effects of panaxynol and panaxydol on HL60 cells and investigated their mechanism of action. Cell growth inhibition of panaxynol and panaxydol were determined by trypan blue dye exclusion assays. Apoptosis of cells was revealed by morphological observation, analysis for nuclear DNA distribution and by annexin V-FITC/ PI staining using flow cytometry. It was found that panaxynol and panaxydol markedly inhibited proliferation of HL60 cells in a time- and dose-dependent manner via an apoptotic pathway. In concern with these ?ndings, Western blot analysis showed proteolytic activation of PKCδ, caspase-3 activation and cleavage of poly (ADP [adenosine diphosphate]-ribose) polymerase in HL60 cells treated by panaxynol and panaxydol. In conclusion, panaxynol and panaxydol have profound effects on growth and apoptosis of HL60 cells, suggesting those substances are worthy of further exploration as potential anti-cancer agents.
Características genéticas da leucemia promielocítica aguda de novo
Leal, Aline M.;Kumeda, Cristina A.;Velloso, Elvira D. R. P.;
Revista Brasileira de Hematologia e Hemoterapia , 2009, DOI: 10.1590/S1516-84842009005000088
Abstract: acute promyelocytic leukemia (apl) is characterized by structural chromosomal abnormalities involving the rarα (retinoic acid receptor a) gene located on the long arm of chromosome 17 (17q21) that lead to the formation of chimeric genes and fusion oncoproteins. in about 98% of cases, the rarα gene is fused to the pml gene, the result of a reciprocal chromosomal translocation t(15;17)(q22;q21) and in the other 2% of cases the rarα gene may be fused to other genes, leading to the formation of fusion proteins known generically as x-rarα. acute promyelocytic leukemia is an example of a hematologic malignancy where there is a combination of genetic and epigenetic (acetylation, deacetylation and methylation) changes in the leukemogenesis process, chromosome structural changes that affect the dynamic equilibrium of chromatin in the promoter region of some genes. the use of molecular techniques that improve genetic diagnosis and the development of targeted molecular therapy have provided a high cure rate of this disorder.
Page 1 /1656
Display every page Item

Copyright © 2008-2017 Open Access Library. All rights reserved.